{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:33:11Z","timestamp":1790299991132,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mucosal healing has been associated with long-term response to therapy for Crohn disease (CD). However, little is known about the significance of terminal ileum (TI) transmural thickness in predicting clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective observational cohort study, we examined the association of an index ultrasonographic assessment of TI thickness during the maintenance phase and the subsequent clinical outcome of CD in a cohort of patients treated with infliximab (IFX). Treatment failure was defined as treatment discontinuation because of lack of efficacy, a need for dose escalation, or surgery. Clinical response was defined as treatment continuation in the absence of any of the aforementioned failure criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty patients with CD receiving IFX therapy were included in the study. The patients were followed for a median of 16 months (5-24 months) after an index intestinal ultrasound. Thirty-eight patients (63.3%) maintained response to the therapy and 22 patients (36.6%) failed the treatment, with a mean follow up of 10.5 months (6.5-17 months) vs 9.25 months (1-10.25 months), respectively. On univariate analysis, the only variables differing between treatment response and failure were a TI thickness of 2.8 vs 5 mm (P &amp;lt; 0.0001) and an IFX trough level of 6.6 vs 3.9 \u00b5g\/mL (P = 0.008).<\/jats:p>\n                  <jats:p>On multivariable analysis, only a small bowel thickness of \u22654 mm was associated with the risk of treatment failure (odds ratio, 2.9; 95% CI, 1.49-5.55; P = 0.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings suggest that transmural thickness of \u22654 mm can predict subsequent treatment failure in patients with CD treated using IFX, indicating transmural thickness &amp;lt;4 mm as a potential novel valuable therapeutic target.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izaa219","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T17:07:01Z","timestamp":1598893621000},"page":"1619-1625","source":"Crossref","is-referenced-by-count":22,"title":["Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-4263","authenticated-orcid":false,"given":"Ahmad","family":"Albshesh","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Ungar","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Eliakim","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Carter","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"2022092121275989800_CIT0001","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121275989800_CIT0002","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ibd\/izy132","article-title":"Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn\u2019s disease","volume":"24","author":"Papamichael","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121275989800_CIT0003","first-page":"549","article-title":"Association of induction infliximab levels with clinical response in perianal Crohn\u2019s disease","volume":"11","author":"Davidov","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2022092121275989800_CIT0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1148\/radiol.2361040799","article-title":"Role of US in detection of Crohn disease: meta-analysis","volume":"236","author":"Fraquelli","year":"2005","journal-title":"Radiology."},{"key":"2022092121275989800_CIT0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/gut.50.4.490","article-title":"Bowel ultrasound in assessment of Crohn\u2019s disease and detection of related small bowel strictures: a prospective comparative study versus x ray and intraoperative findings","volume":"50","author":"Parente","year":"2002","journal-title":"Gut."},{"key":"2022092121275989800_CIT0006","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn\u2019s disease complicated by strictures: a systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut."},{"key":"2022092121275989800_CIT0007","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1572-0241.2003.07521.x","article-title":"Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn\u2019s disease: a prospective comparative study","volume":"98","author":"Maconi","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"2022092121275989800_CIT0008","article-title":"Feasibility of bedside bowel ultrasound performed by a gastroenterologist for detection and follow-up of inflammatory bowel disease","volume":"19:139\u2013142","author":"Carter","year":"2017","journal-title":"Isr Med Assoc J."},{"key":"2022092121275989800_CIT0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2022092121275989800_CIT0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gut.44.1.6","article-title":"Transabdominal bowel sonography in Crohn\u2019s disease","volume":"44","author":"McLean","year":"1999","journal-title":"Gut."},{"key":"2022092121275989800_CIT0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ecco-jcc\/jjx111","article-title":"Validity of contrast-enhanced ultrasonography and dynamic contrast-enhanced MR enterography in the assessment of transmural activity and fibrosis in Crohn\u2019s disease","volume":"12","author":"Wilkens","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2022092121275989800_CIT0012","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/apt.15190","article-title":"One-year clinical outcomes with biologics in Crohn\u2019s disease: transmural healing compared with mucosal or no healing","volume":"49","author":"Castiglione","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092121275989800_CIT0013","doi-asserted-by":"crossref","first-page":"P514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"Simple index of Crohn\u2019s disease activity","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet."},{"key":"2022092121275989800_CIT0014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121275989800_CIT0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab\u2019)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut."},{"key":"2022092121275989800_CIT0016","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00247-016-3555-5","article-title":"MR enterography: how to deliver added value","volume":"46","author":"Dillman","year":"2016","journal-title":"Pediatr Radiol."},{"key":"2022092121275989800_CIT0017","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ibd\/izy091","article-title":"Real-time interobserver agreement in bowel ultrasonography for diagnostic assessment in patients with Crohn\u2019s disease: an international multicenter study","volume":"24","author":"Calabrese","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121275989800_CIT0018","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cgh.2013.01.015","article-title":"Accuracy of small-intestine contrast ultrasonography, compared with computed tomography enteroclysis, in characterizing lesions in patients with Crohn\u2019s disease","volume":"11","author":"Calabrese","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121275989800_CIT0019","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2036.2011.04710.x","article-title":"Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn\u2019s disease","volume":"34","author":"Pan\u00e9s","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2022092121275989800_CIT0020","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2471070611","article-title":"Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies","author":"Horsthuis","year":"2008","journal-title":"Radiology."},{"key":"2022092121275989800_CIT0021","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/MIB.0000000000000727","article-title":"Medical imaging in small bowel Crohn\u2019s disease\u2014computer tomography enterography, magnetic resonance enterography, and ultrasound: \u201cWhich one is the best for what?\u201d","volume":"22","author":"Greenup","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121275989800_CIT0022","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/ecco-jcc\/jjy093","article-title":"Comparative accuracy of bowel ultrasound versus magnetic resonance enterography in combination with colonoscopy in assessing Crohn\u2019s disease and guiding clinical decision-making","volume":"12","author":"Allocca","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2022092121275989800_CIT0023","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/MIB.0000000000000706","article-title":"Bowel ultrasonography in the management of Crohn\u2019s disease. a review with recommendations of an international panel of experts","volume":"22","author":"Calabrese","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121275989800_CIT0024","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2016.10.040","article-title":"Use of intestinal ultrasound to monitor Crohn\u2019s disease activity","volume":"15","author":"Kucharzik","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022092121275989800_CIT0025","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/ecco-jcc\/jjv105","article-title":"Clinic-based point of care transabdominal ultrasound for monitoring Crohn\u2019s disease: impact on clinical decision making","volume":"9","author":"Novak","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2022092121275989800_CIT0026","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s00247-017-3848-3","article-title":"Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy","volume":"47","author":"Dillman","year":"2017","journal-title":"Pediatr Radiol."},{"key":"2022092121275989800_CIT0027","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4291\/wjgp.v5.i4.457","article-title":"Role of bowel ultrasound in the management of postoperative Crohn\u2019s disease","volume":"5","author":"Ercole","year":"2014","journal-title":"World J Gastrointest Pathophysiol."},{"key":"2022092121275989800_CIT0028","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/ibd.20948","article-title":"Severity of postoperative recurrence in Crohn\u2019s disease: Correlation between endoscopic and sonographic findings","volume":"15","author":"Calabrese","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121275989800_CIT0029","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/MIB.0000000000001143","article-title":"Transmural healing is associated with improved long-term outcomes of patients with Crohn\u2019s disease","volume":"23","author":"Fernandes","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2022092121275989800_CIT0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/2050640619878974","article-title":"Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn\u2019s disease","volume":"8","author":"Ungar","year":"2020","journal-title":"United European Gastroenterol J."},{"key":"2022092121275989800_CIT0031","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","article-title":"Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the POETIC study","volume":"113","author":"Ungar","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2022092121275989800_CIT0032","first-page":"19","article-title":"Crohn\u2019s disease","volume":"381","author":"Baumgart","year":"2013","journal-title":"Lancet."},{"key":"2022092121275989800_CIT0033","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review","volume":"14","author":"Colombel","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2022092121275989800_CIT0034","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00535-018-1479-6","article-title":"The state of the art on treatment of Crohn\u2019s disease","volume":"53","author":"Shi","year":"2018","journal-title":"J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/10\/1619\/45965272\/ibd_26_10_1619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/10\/1619\/45965272\/ibd_26_10_1619.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T21:38:43Z","timestamp":1663796323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/10\/1619\/5898844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,29]]},"published-print":{"date-parts":[[2020,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaa219","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,8,29]]}}}